Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment is innovative (“off-label”). Terms of Use
Patient is from Papua New Guinea, where he has been living for more than 17 years. Improvements noted in chronic central post-stroke pain, motor function and balance documented within minutes of treatment, 18 months after stroke. Treatment at the Institute of Neurological Recovery in Boca Raton, Florida on April 13, 2017.
Disclaimer: Individual results vary, not all patients respond. Additional doses may be necessary to maintain the clinical response. Treatment for these indications is innovative (“off-label”). Please see the Terms of Use. The method of off-label treatment utilized is a patented invention of the INR. Copyright 2018 INR PLLC, all rights reserved.
Edward Tobinick, M.D., the founder and Director of the Institute of Neurological Recovery, invented the remarkable breakthrough perispinal etanercept treatment for stroke and chronic brain injury, first used in 2010, now, in 2023, with thousands of patients treated from 91 countries.
In October 2018, the Australian Government announced their designation of substantial funding to study perispinal etanercept(PSE) for treatment of stroke. On January 3, 2020 a university, double-blind, randomized, placebo-controlled, clinical trial confirmed the efficacy of perispinal etanercept for treatment of chronic, post-stroke pain. Dr. Tobinick was instrumental in the design of the university study.
The INR accepts patients for treatment from all parts of the world, and has treated patients from every populated continent of the world.
Scientific articles from hundreds of academic scientists around the world have cited INR publications.
